GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Pharmaceutical Commerce
CrossRef Fucoxanthin Suppresses Lipid Accumulation and Inflammatory Responses in FFA-Induced Hepatocyte Models via the EGR2-CD36 Axis Xiangyu Li, Chen Yang, Qionghui Chen, Xianchuan Xu, Lian Wang, Peng Zhang, Qiang Hu, Danxiang Han, Aiqun Yu, Jing Jiang, Qizhou Lian Molecules .2026
OBrien R, OMalley D (2020) The glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of irritable bowel syndrome
Heart rate should be monitored at regular intervals consistent with usual clinical practice
These factors can make a meaningful difference when selecting products for ongoing research projects